Bronchodilators Market Report by Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), Drug Type (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), Route of Administration (Oral, Injection, Inhaler), and Region 2025-2033

Bronchodilators Market Report by Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), Drug Type (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), Route of Administration (Oral, Injection, Inhaler), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A4184

Market Overview:

The global bronchodilators market size reached USD 39.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 57.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033.

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 39.3 Billion
Market Forecast in 2033
USD 57.7 Billion
Market Growth Rate 2025-2033 4.15%


Bronchodilators are medications used to treat patients suffering from long-term conditions of narrow and inflamed airways, such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD). They help relieve associated symptoms by relaxing the muscles around the airways or bronchi, clearing mucus from the lungs, and making breathing easier. They are available in the form of tablets, liquid, nebulizer solutions, and metered-dose and dry powder inhalers. Nowadays, bronchodilators are also utilized to enhance the effect of inhaled corticosteroids, which act as a primary treatment to reduce inflammation and prevent flare-ups in asthma.

Bronchodilators Market Trends:

A significantly rising number of patients with acute respiratory infections due to coronavirus disease (COVID-19) represents one of the key factors influencing the need for bronchodilators across the globe. Apart from this, increasing levels of air pollution, the rising number of smokers, and the growing prevalence of infectious diseases around the world are contributing to the risk of developing lung conditions. This is acting as another growth-inducing factor of the market. In addition, lung function declines gradually with age, which can make breathing slightly difficult. This, along with the increasing geriatric population and a considerable rise in consumer spending capacities, is driving the market. Other factors, such as improving healthcare infrastructure and diagnostic modalities and rising shift towards non-invasive procedures, are also propelling the market growth. Furthermore, several new classes of bronchodilators that can help overcome the limitations of existing products are in the preclinical phase stage. In confluence with this, health agencies of numerous countries are supporting research and development (R&D) activities for bronchodilators, which is anticipated to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global bronchodilators market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on indication, drug type and route of administration.

Breakup by Indication:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
     

Breakup by Drug Type:

  • Sympathomimetics
  • Anticholinergics
  • Phosphodiesterase Inhibitor
  • Combination Drugs
     

Breakup by Route of Administration:

  • Oral
  • Injection
  • Inhaler
     

Breakup by Region:

Bronchodilators Market Report

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Indication, Drug Type, Route of Administration, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global bronchodilators market was valued at USD 39.3 Billion in 2024.

We expect the global bronchodilators market to exhibit a CAGR of 4.15% during 2025-2033.

The rising pollution levels, along with the increasing prevalence of numerous chronic respiratory diseases, such as asthma, Chronic Obstructive Pulmonary Disease (COPD), allergic reactions, etc., are primarily driving the global bronchodilators market.

The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of bronchodilators, owing to the growing number of the coronavirus infected patients with acute respiratory conditions.

Based on the indication, the global bronchodilators market can be segmented into asthma, Chronic Obstructive Pulmonary Disease (COPD), and others. Currently, asthma holds the majority of the total market share.

Based on the drug type, the global bronchodilators market has been divided into sympathomimetics, anticholinergics, phosphodiesterase inhibitor, and combination drugs. Among these, anticholinergics currently exhibit a clear dominance in the market.

Based on the route of administration, the global bronchodilators market can be categorized into oral, injection, and inhaler. Currently, inhaler accounts for the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global bronchodilators market include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Vectura Group plc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Bronchodilators Market Report by Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), Drug Type (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), Route of Administration (Oral, Injection, Inhaler), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials